Nasdaq
$0.5177▲ 1.51%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $6.4MShares out 12.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 8.28Pre-market26.08.28 21:308-KKey event#●●●#●●●#●●●
Aprea Therapeutics, Inc.
Aprea Therapeutics expanded its intellectual property portfolio to 28 issued and 30 pending patents as of August 28, 2026. This move strengthens the patent protection for its key precision oncology programs, including the WEE1 inhibitor APR-1051 and the ATR inhibitor ATRN-119, to support future clinical development and long-term value.…more
$0.5177+1.51%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.12Pre-market26.08.12 21:4010-QEarnings
Aprea Therapeutics, Inc.
Aprea Therapeutics filed its quarterly report (10-Q) for the period ended June 30, 2026, reporting 12,591,136 shares of common stock outstanding as of August 12, 2026. While the company continues the clinical development of product candidates such as APR-1051, it highlights significant risks regarding future capital requirements and clinical trial outcomes.…more
$0.5177+1.51%vs prev closeView filingShare - 8.12Pre-market26.08.12 21:358-KKey event
Aprea Therapeutics, Inc.
Aprea Therapeutics reported $41.2 million in cash and cash equivalents as of June 30, 2026, providing sufficient runway through the first quarter of 2028. The company is currently advancing its Phase 1 trial (ACESOT-1051) for the oral WEE1 inhibitor APR-1051, with accelerated enrollment targeting patients with uterine serous carcinoma and ovarian cancer.…more
$0.5177+1.51%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.16Pre-market26.10.16 21:30#●●●#●●●
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on WEE1 Inhibition
Aprea Therapeutics will host a virtual panel discussion on the state of WEE1 inhibition in precision oncology ahead of the ESMO Congress 2026. The event aims to discuss the scientific and market perspectives surrounding the company's lead clinical program, APR-1051.…more
$0.5177+1.51%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.5Pre-market26.10.05 21:30
●●●●●●●● ●●●●● ●●●●●●
Aprea Therapeutics announced its participation in the 2026 Maxim Growth Summit and the Regional Biotechnology Conference this October. These scheduled appearances are standard investor relations activities and do not provide immediate material impact on the stock.…more
$0.5177+1.51%vs prev close - 9.22Pre-market26.09.22 21:30
●●●●●●●● ●●●●● ●●●●●●
Aprea Therapeutics will present updated interim results from its Phase 1 study of the WEE1 inhibitor APR-1051 in patients with advanced solid tumors. The data is scheduled for an oral presentation at the 38th EORTC-NCI-AACR Symposium in November 2026.…more
$0.5177+1.51%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report